Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 39.8% in March

Kamada Ltd. (NASDAQ:KMDA) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 34,200 shares, a decrease of 39.8% from the March 15th total of 56,800 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 227,000 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on KMDA shares. Benchmark assumed coverage on Kamada in a report on Friday, March 21st. They set a “buy” rating and a $15.00 price objective on the stock. StockNews.com cut shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 25th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th.

Kamada Price Performance

Shares of NASDAQ:KMDA traded up $0.15 during trading hours on Thursday, hitting $6.50. 97,478 shares of the company’s stock traded hands, compared to its average volume of 84,362. The business has a fifty day moving average price of $6.91 and a 200-day moving average price of $6.38. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16. The firm has a market capitalization of $373.62 million, a P/E ratio of 23.21, a price-to-earnings-growth ratio of 0.97 and a beta of 1.07.

Kamada Announces Dividend

The business also recently declared a — dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were issued a $0.20 dividend. The ex-dividend date of this dividend was Monday, March 17th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC grew its stake in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Aristides Capital LLC increased its stake in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 6,850 shares during the period. Geode Capital Management LLC raised its holdings in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kamada during the 4th quarter worth about $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Kamada during the 3rd quarter valued at about $77,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.